Not available
Quote | Intersect ENT Inc. (NASDAQ:XENT)
Last: | $28.24 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $28.24 |
High: | $0 |
Low: | $0 |
Volume: | 14,512 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Intersect ENT Inc. (NASDAQ:XENT)
Eight new deals announced last week. Chicken Soup acquires Redbox in a 'take-under' at a massive discount. Following Elon Musk's tweet last week, stating that the Twitter deal is temporarily on hold, Twitter shares fell as low as $40.01 on Friday, May 13, 2022. For further d...
Two of the three new deals announced last week were potential deals in the works. Black Knight entered into a definitive agreement to be acquired by Intercontinental Exchange in a deal valued at $13.1 billion. Welltower made a nearly $5 billion all-cash bid for Healthcare Realty T...
Message Board Posts | Intersect ENT Inc. (NASDAQ:XENT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $XENT News Article - Why Intersect ENT Shot 12% Higher on Friday | whytestocks | investorshangout | 08/06/2021 8:35:46 PM |
whytestocks: $XENT News Article - INTERSECT ENT ALERT: Bragar Eagel & Squire, P.C. Investigates Sale | whytestocks | investorshangout | 08/06/2021 5:45:47 PM |
whytestocks: $XENT News Article - Intersect ENT Reports Second Quarter 2021 Financial Results | whytestocks | investorshangout | 08/06/2021 2:35:48 PM |
whytestocks: $XENT News Article - U.S Nationwide Commercial Availability of the VenSure(TM) Balloon | whytestocks | investorshangout | 07/26/2021 2:55:50 PM |
whytestocks: $XENT News Article - Intersect ENT Reports Second Quarter 2020 Financial Results | whytestocks | investorshangout | 08/04/2020 3:15:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL ® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including a...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third qu...
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to...